Your browser doesn't support javascript.
loading
Prioritizing therapeutic targets using patient-derived xenograft models.
Lodhia, K A; Hadley, A M; Haluska, P; Scott, C L.
Affiliation
  • Lodhia KA; Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Hadley AM; Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
  • Haluska P; Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Scott CL; Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia. Electronic address: scottc@wehi.edu.au.
Biochim Biophys Acta ; 1855(2): 223-34, 2015 Apr.
Article in En | MEDLINE | ID: mdl-25783201
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Resistance, Neoplasm / Xenograft Model Antitumor Assays / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Biochim Biophys Acta Year: 2015 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Resistance, Neoplasm / Xenograft Model Antitumor Assays / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Biochim Biophys Acta Year: 2015 Document type: Article Affiliation country: Country of publication: